Literature DB >> 21890289

Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density.

Gal Dubnov-Raz1, Harri Hemilä, Yael Vurembrand, Jacob Kuint, Ayala Maayan-Metzger.   

Abstract

BACKGROUND: Selective serotonin reuptake inhibitors (SSRI) are commonly used to treat depression in pregnant women. Several adverse effects of prenatal SSRI exposure on the offspring have been described, including decreased growth. SSRI use by adults decreases bone mineral density, but this effect had not been examined in infants. AIM: To examine growth parameters and bone mineral density of infants born to mothers using SSRIs during pregnancy. STUDY
DESIGN: Anthropometric variables and bone density were compared between 40 newborns exposed to SSRIs in utero, and 40 gestational-age matched control infants. Tibial bone speed of sound, a marker of bone density and strength, was measured using quantitative ultrasound. The difference in bone speed of sound between the two groups was compared using linear models, adjusting for relevant confounders.
RESULTS: Infants in the SSRI-exposed group were shorter, with a marginal statistical significance (49.3±2.1 vs. 50.1±1.3cm, p=0.07), while mean birth weight did not differ substantially between study groups. Head circumference was significantly smaller in the SSRI group (33.8±1.2 vs 34.4±1.1cm, p=0.005), remaining so even after adjustment for several confounders. No considerable difference was found in the bone speed of sound between SSRI-exposed infants and controls (3011±116 vs. 3029±129m/s).
CONCLUSIONS: We found no evidence that prenatal SSRI exposure hindered neonatal bone quality, yet a marginally shorter length and a smaller head circumference raise the possibility of an effect on bone growth. We conclude that the effect of SSRIs on fetal bone density seems minimal or absent.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890289     DOI: 10.1016/j.earlhumdev.2011.08.005

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  12 in total

1.  The use of antidepressants is linked to bone loss: A systematic review and metanalysis.

Authors:  Michele Mercurio; Renato de Filippis; Giovanna Spina; Pasquale De Fazio; Cristina Segura-Garcia; Olimpio Galasso; Giorgio Gasparini
Journal:  Orthop Rev (Pavia)       Date:  2022-10-13

2.  Peripartum dietary supplementation of a small-molecule inhibitor of tryptophan hydroxylase 1 compromises infant, but not maternal, bone.

Authors:  Samantha R Weaver; Hannah P Fricke; Cynthia Xie; Robert J Aiello; Julia F Charles; Laura L Hernandez
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-23       Impact factor: 4.310

3.  A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns.

Authors:  Deidra A Ansah; Benjamin E Reinking; Tarah T Colaizy; Robert D Roghair; Sarah E Haskell
Journal:  Neonatology       Date:  2019-03-05       Impact factor: 4.035

4.  Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study.

Authors:  Ravisha Wadhwa; Manoj Kumar; Yam Nath Paudel; Ramsha Iqbal; Priyanka Kothari; Ritu Trivedi; Divya Vohora
Journal:  J Bone Miner Metab       Date:  2018-01-29       Impact factor: 2.626

Review 5.  Could use of Selective Serotonin Reuptake Inhibitors During Lactation Cause Persistent Effects on Maternal Bone?

Authors:  Samantha R Weaver; Laura L Hernandez
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-03-30       Impact factor: 2.673

6.  Citalopram and sertraline exposure compromises embryonic bone development.

Authors:  D Fraher; J M Hodge; F M Collier; J S McMillan; R L Kennedy; M Ellis; G C Nicholson; K Walder; S Dodd; M Berk; J A Pasco; L J Williams; Y Gibert
Journal:  Mol Psychiatry       Date:  2015-09-08       Impact factor: 15.992

7.  Does fetal exposure to SSRIs or maternal depression impact infant growth?

Authors:  Katherine L Wisner; Debra L Bogen; Dorothy Sit; Mary McShea; Carolyn Hughes; David Rizzo; Andrea Confer; James Luther; Heather Eng; Stephen W Wisniewski
Journal:  Am J Psychiatry       Date:  2013-05       Impact factor: 18.112

8.  Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure.

Authors:  Rebecca C Knickmeyer; Samantha Meltzer-Brody; Sandra Woolson; Robert M Hamer; J Keith Smith; Kenneth Lury; John H Gilmore
Journal:  Neuropsychopharmacology       Date:  2014-05-20       Impact factor: 7.853

9.  Effects of Citalopram on Sutural and Calvarial Cell Processes.

Authors:  Emily Durham; Serena Jen; Lin Wang; Joseph Nasworthy; Mohammed Elsalanty; Seth Weinberg; Jack Yu; James Cray
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

10.  Serotonin: a novel bone mass controller may have implications for alveolar bone.

Authors:  Carlo Galli; Guido Macaluso; Giovanni Passeri
Journal:  J Negat Results Biomed       Date:  2013-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.